



## **EXIT071 awarded 1.9M by Biotech Booster to advance exosome isolation technology**

Leiden, The Netherlands, April 10, 2025

**EXIT071, a Dutch deep-tech company and spin-off from Leiden University, has been awarded €1.9 million by Biotech Booster to accelerate the development of EXOBOOSTER, a project aimed at delivering novel technology for biomarker discovery in drug development and the diagnostic industry.**

EXIT071 has developed a platform technology, the EXIT (EXosome Isolation Tool), for scalable exosome isolation and biomarker analysis. Exosomes are nanosized extracellular vesicles present in body fluids, carrying molecular signatures of their originating cells, making them highly valuable for diagnostics and understanding disease mechanisms. EXIT071's platform is based on its patented depletion zone isotachopheresis technology, invented at Leiden University, enabling simultaneous separation and enrichment of exosomes in a microfluidic chip. This technology seamlessly integrates with molecular analysis methods such as mass spectrometry, sequencing, PCR, enabling automated workflows for high-throughput biomarker analysis.

EXIT071 platform aims to enhance the efficiency and scalability of exosome isolation, a critical step in unlocking the potential of extracellular vesicles as biomarkers for disease detection and treatment monitoring. By improving current isolation technologies, EXIT071 seeks to provide researchers, companies and clinicians with more reliable and high-yield solutions, ultimately facilitating breakthroughs in precision medicine.

Biotech Booster's funding will enable EXIT071 to perform key platform improvements and commercialize the exosome isolation platform, bringing us closer to transforming how biomarkers are utilized in drug discovery and diagnostics. With this funding, EXIT071 plans to expand its R&D capabilities, strengthen its strategic partnerships, and accelerate the translation of its cutting-edge technology into real-world applications.

### **About EXIT071**

EXIT071 is a Dutch deep-tech company, spin-off from Leiden University, based at the Leiden Bio Science Park. The company is dedicated to developing advanced exosome isolation technologies for biomarker discovery, diagnostics, and therapeutic applications. By leveraging its proprietary innovations, EXIT071 aims to accelerate the integration of exosome-based solutions into precision medicine.

**Email:** [info@exit071.com](mailto:info@exit071.com)

**Website:** [www.exit071.com](http://www.exit071.com)

### **About Biotech Booster**

Biotech Booster is a Dutch national program to stimulate commercialization of biotechnology research from academia and small industry. The program offers mentorship, financial support and networking opportunities, to guide founders from the idea stage to developing an investable and commercial proposition. The program runs from 2022 – 2031 and is financed by the National Growth Fund with a subsidy of ~ € 250M, to which cofinancing from partners will be added.

**Email:** [office@biotechbooster.nl](mailto:office@biotechbooster.nl)

**Website:** [www.biotechbooster.nl](http://www.biotechbooster.nl).